1. Home
  2. ANNX vs NX Comparison

ANNX vs NX Comparison

Compare ANNX & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.79

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

HOLD

Current Price

$19.80

Market Cap

915.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
NX
Founded
2011
1927
Country
United States
United States
Employees
N/A
7071
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
972.5M
915.5M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
ANNX
NX
Price
$5.79
$19.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$16.50
$28.00
AVG Volume (30 Days)
2.2M
309.6K
Earning Date
05-11-2026
06-04-2026
Dividend Yield
N/A
1.64%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,837,641,000.00
Revenue This Year
N/A
$4.26
Revenue Next Year
$16,320.74
$1.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.81
52 Week Low
$1.60
$11.04
52 Week High
$7.18
$22.90

Technical Indicators

Market Signals
Indicator
ANNX
NX
Relative Strength Index (RSI) 47.71 53.67
Support Level $4.79 $18.92
Resistance Level $6.56 $20.08
Average True Range (ATR) 0.29 0.73
MACD -0.06 -0.05
Stochastic Oscillator 8.43 41.23

Price Performance

Historical Comparison
ANNX
NX

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: